Faron Pharmaceuticals: Positive BEXMAB Study Update
Research Note
2023-07-19
10:55
Redeye leaves a note following Faron’s recent study update from the phase I/II BEXMAB study with its lead candidate, bexmarilimab. We are encouraged by the continued positive progress and the candidate’s favorable response to treatment in relapsed/refractory AML and MDS.
KS
Kevin Sule
Disclosures and disclaimers